Dear Editor,

Refractory agitation in infants is frequently met at the pediatric intensive care unit (PICU) \[[@CR1]\]. Finding the right sedative to remedy this can be challenging, particularly as previous research has shown that agitation in critically ill children may also be a marker for pediatric delirium (PD) \[[@CR1]\].

Over the last 2 years, four very young critically ill infants (two girls, two boys; age range 7--14 months; mechanically ventilated and receiving analgosedation according to international guidelines) presented with refractory agitation. Description of the context and diagnostic approach in our unit can be found in previous publications \[[@CR1]\]. Two of the four children received alimemazine in order to remedy agitation that was present in spite of adequate analgosedation; however, agitation worsened. In the two other infants, analgosedative medication was being tapered off slowly when the children developed agitation; despite reinstatement of analgosedative medication at its original dose or even higher, agitation continued.

Although the *Diagnostic and Statistical Manual*, fourth edition, text revision (DSM-IV-TR) states that cognitive change must be observed in order to diagnose delirium, it has been argued that refractory agitation---as observed in these four infants, after exclusion of other logical explanations---may be more usefully considered as an expression of PD \[[@CR1], [@CR2]\], which requires a different approach.

Delirium superimposed on withdrawal may present as an excess in the number, intensity, duration, and/or responsiveness of the symptoms normally associated with withdrawal \[[@CR2]\]. In the first two children, sedative medication may have induced PD through anticholinergic mechanisms (see below). In the other two children, PD was superimposed on withdrawal symptoms, as evidenced by nonresponse to reinstatement of the original sedative.

A recent consensus guideline on sedation and analgesia in critically ill children suggested that promethazine or alimemazine (trimeprazine), both H1-receptor antagonists, may be considered for sedation \[[@CR3]\]. However, these medications are characterized not only by sedation but also by strong anticholinergic side-effects, which may provoke agitation rather than sedation in children, given that cholinergic and dopaminergic neurotransmission is linked to delirium pathophysiology through, respectively, hypocholinergic and/or hyperdopaminergic states \[[@CR4]\]. Thus, H1-antagonists with their strong anticholinergic and weak D2-blocking effects may kindle and aggravate refractory agitation. Haloperidol, however, with its weak anticholinergic and strong D2-blocking effects, may constitute a more effective treatment \[[@CR5], [@CR6]\].

Haloperidol is a well-studied drug with few side-effects and has been successfully used for agitation in young children \[[@CR5], [@CR6]\]. Haloperidol and alimemazine both have low risks of cardiac side-effects---alimemazine may carry a higher risk---and rarely may induce malignant neuroleptic syndrome. The four children were successfully treated with haloperidol intravenously according to a minimal treatment schedule (Table [1](#Tab1){ref-type="table"}).Table 1Minimal intravenous haloperidol dosage scheme for delirium in pediatric patientsAge (years)Weight (kg)Loading dose (mg IV)Haloperidol starting dosage (mg/kg/24 h i.v.)0--13.5--100.050.011--310--150.150.0253--18\>150.250.05Maximal haloperidol dosage in adults is approximately 5 mg/24 h i.v.

An empirical approach of steadily titrating and close monitoring is advocated in order to find the right dosage, maneuvering between clinical response and side-effects. One patient developed an intermittent oculogyric crisis that was successfully treated with 50 μg/kg biperiden i.v.

We conclude that refractory agitation at the PICU may be a marker of underlying PD, and that haloperidol rather than an H1-receptor antagonist may give satisfactory results.

None.
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